CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study

Part of paid clinical trials in Charlotte, North Carolina.

Sponsor
Wake Forest University Health Sciences
Study ID
NCT06644625
Status
Recruiting
Apply to this trial

Conditions

  • Monoclonal Gammopathy of Undetermined Significance (MGUS)
  • Multiple Myeloma
  • Multiple Myeloma Progression
  • Plasma Cell Disorders
  • Smoldering Multiple Myeloma (SMM)

Eligibility Criteria

Sex
ALL
Age
30 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • Blood draw for the laboratory assessment — OTHER
    Screening blood sample collection to test for MGUS

Study Details

The purpose of this study is to identify multiple myeloma in the precancerous MGUS stage in order to reduce the risk of delayed diagnosis of multiple myeloma, decrease morbidity related to multiple myeloma at progression, and improve long term outcomes.

Key Dates

Start date
Mar 1, 2025
Status verified
Jan 2026
Primary completion
Jan 31, 2035
Completion
Jan 31, 2035

Study Design

Enrollment
1,665 participants (estimated)

Arms

  • Arm: MGUS and Smoldering Multiple Myeloma
    Participants diagnosed with MGUS and smoldering multiple myeloma
  • Arm: Other Plasma Cell Disorders
    Participants diagnosed with other plasma cell disorders

Primary Outcome Measure

Number of Participants who were Enrolled [ Time Frame: Baseline, for an accrual period of one year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Atrium Health Levine CancerCharlotteNorth Carolina28204
Margarita Dzhanumova
[email protected]
704-754-3768
Manisha Bhutani, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Charlotte, NC

By condition
Multiple myeloma
By specialty
OncologyBlood cancer
By research site
Atrium Health Levine Cancer· Charlotte, NC

Related Studies